{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:33:07Z","timestamp":1782829987531,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>It is unknown whether safety and clinical endpoints by use of sacubitril\/valsartan (an angiotensin receptor\u2013neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high-risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril\/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and\/or pulmonary congestion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients (n\u2009=\u20095661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death. Safety was defined as symptomatic hypotension, hyperkalaemia &amp;gt;5.5\u2009mmol\/L, or permanent drug discontinuation. A total of 2338 patients (41%) were treated with MRA. Safety of ARNI compared to ramipril was not altered significantly by \u00b1\u2009MRA, and both groups had similar increase in symptomatic hypotension with ARNI. In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI (p\u2009&amp;gt;\u20090.05 for all comparisons). The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR]MRA 0.96, 95% confidence interval [CI] 0.77\u20131.19 and HRMRA\u2013 0.87, 95% CI 0.71\u20131.05, for the primary endpoint; p =\u20090.51 for interaction\u2009[Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator-reported endpoints were evaluated (p\u2009=\u20090.61 for interaction).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post-MI setting in patients with LVSD and\/or congestion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3079","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T02:59:27Z","timestamp":1699325967000},"page":"130-139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sacubitril\/Valsartan Compared to Ramipril in High-Risk Post-Myocardial Infarction Patients Stratified According to Use of Mineralocorticoid Receptor Antagonists: Insight from the PARADISE MI Trial"],"prefix":"10.1093","volume":"26","author":[{"given":"Morten","family":"Schou","sequence":"first","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Michael","family":"Miao","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Cardiology Service, Sanatorio Modelo Quilmes , Quilmes ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karola","family":"Jering","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finnian","family":"McCausland","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine (F.R.M.), Brigham and Women's Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Nu\u00f1ez","family":"Villota","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Hospital Cl\u00ednico Universitario , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Lucien","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Montr\u00e9al Heart Institute, University of Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freny Vaghaiwalla","family":"Mody","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System , Los Angeles, CA ,","place":["USA"]},{"name":"Division of Cardiology, University of California , Los Angeles, CA ,","place":["USA"]},{"name":"David Geffen School of Medicine, University of California , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"McGrath","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine (F.R.M.), Brigham and Women's Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Mann","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine , St Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Rigshospitalet, Blegdamsvej, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"2026010913073879200_ejhf3079-bib-0001","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913073879200_ejhf3079-bib-0002","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913073879200_ejhf3079-bib-0003","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0004","first-page":"4","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0005","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913073879200_ejhf3079-bib-0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.121.057429","article-title":"Impact of sacubitril\/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial","volume":"145","author":"Pfeffer","year":"2022","journal-title":"Circulation"},{"key":"2026010913073879200_ejhf3079-bib-0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212","article-title":"Effects of sacubitril\/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy","volume":"9","author":"Okumura","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0009","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1093\/eurheartj\/suab098","article-title":"Does sacubitril\/valsartan work in acute myocardial infarction? The PARADISE-AMI study","volume":"23","author":"Gatto","year":"2021","journal-title":"Eur Heart J Suppl"},{"key":"2026010913073879200_ejhf3079-bib-0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMp1212324","article-title":"Post-hospital syndrome \u2013 An acquired, transient condition of generalized risk","volume":"368","author":"Krumholz","year":"2013","journal-title":"N Engl J Med"},{"key":"2026010913073879200_ejhf3079-bib-0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ejhf.2418","article-title":"Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017","volume":"24","author":"Zahir","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: Rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0013","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913073879200_ejhf3079-bib-0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913073879200_ejhf3079-bib-0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.recesp.2021.05.017","article-title":"Survival analyses in cardiovascular research, part I: The essentials","volume":"75","author":"Rossello","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026010913073879200_ejhf3079-bib-0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.recesp.2021.06.027","article-title":"Survival analyses in cardiovascular research, part II: Statistical methods in challenging situations","volume":"75","author":"Rossello","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026010913073879200_ejhf3079-bib-0017","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2021.06.024","article-title":"Primary and secondary outcome reporting in randomized trials: JACC state-of-the-art review","volume":"78","author":"Pocock","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913073879200_ejhf3079-bib-0018","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","article-title":"Empagliflozin in patients post myocardial infarction: Rationale and design of the EMPACT-MI trial","volume":"253","author":"Harrington","year":"2022","journal-title":"Am Heart J"},{"key":"2026010913073879200_ejhf3079-bib-0019","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2022.2847","article-title":"Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction: A review","volume":"7","author":"Harrington","year":"2022","journal-title":"Butler J JAMA Cardiol"},{"key":"2026010913073879200_ejhf3079-bib-0020","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/eurheartj\/ehab717","article-title":"Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI","volume":"43","author":"Pitt","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913073879200_ejhf3079-bib-0021","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"2026010913073879200_ejhf3079-bib-0022","doi-asserted-by":"crossref","DOI":"10.1093\/ehjqcco\/qcad007","article-title":"Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines","author":"Mas-Llado","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/1\/130\/65513938\/eurjhf_26_1_130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/1\/130\/65513938\/eurjhf_26_1_130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:27Z","timestamp":1767982167000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/1\/130\/8328862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3079","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"2023-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}